We are live on ! Find out more
TLP

Tri Locum Partners Portfolio holdings

AUM $713M
1-Year Est. Return 68.92%
This Fund
S&P 500
This Quarter Est. Return
+33.46%
1 Year Est. Return
+68.92%
3 Year Est. Return
+377.81%
5 Year Est. Return
+1,289.15%
10 Year Est. Return
–
AUM
$247M
AUM Growth
-$117M
Cap. Flow
-$139M
Cap. Flow %
-56.36%
Top 10 Hldgs %
58.38%
Holding
95
New
54
Increased
7
Reduced
11
Closed
22

Top Buys

Rank Stock Value
1
WST icon
West Pharmaceutical
WST
+$23M
2
MRK icon
Merck
MRK
+$13M
3
AXSM icon
Axsome Therapeutics
AXSM
+$12M
4
APLS
Apellis Pharmaceuticals
APLS
+$11.8M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$11.7M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$24.2M
2
ARGX icon
argenx
ARGX
+$23.5M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$20.9M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$20.7M
5
LLY icon
Eli Lilly
LLY
+$18M

Sector Composition

Rank Sector Weight
1 Healthcare 90.81%
2 Real Estate 0.3%
3 Industrials 0.1%
4 Financials 0.1%
5 Energy 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIIB icon
76
Biogen
BIIB
$30.5B
– –
-90,551
Closed -$24.2M
BLCO icon
77
Bausch + Lomb
BLCO
$5.84B
– –
-700,525
Closed -$10.7M
CHRS icon
78
Coherus Oncology
CHRS
$194M
– –
-636,943
Closed -$6.12M
CRSP icon
79
CRISPR Therapeutics
CRSP
$4.99B
– –
-36,460
Closed -$2.38M
EW icon
80
Edwards Lifesciences
EW
$51.5B
– –
-171,082
Closed -$14.1M
KYNB
81
Kyntra Bio
KYNB
$28.3M
– –
-2,974
Closed -$967K
GSK icon
82
GSK
GSK
$104B
– –
-409,503
Closed -$12.1M
INSP icon
83
Inspire Medical Systems
INSP
$1.7B
– –
-23,412
Closed -$4.15M
JAZZ icon
84
Jazz Pharmaceuticals
JAZZ
$16.7B
– –
-106,528
Closed -$14.2M
CYPH
85
Cypherpunk Technologies Inc
CYPH
$71.7M
– –
-71,180
Closed -$626K
MRVI icon
86
Maravai LifeSciences
MRVI
$922M
– –
-280,811
Closed -$7.17M
NBIX icon
87
Neurocrine Biosciences
NBIX
$16.2B
– –
-196,390
Closed -$20.9M
NTRA icon
88
Natera
NTRA
$38B
– –
-129,955
Closed -$5.7M
REGN icon
89
Regeneron Pharmaceuticals
REGN
$79.5B
– –
-30,115
Closed -$20.7M
SKIN icon
90
SkinHealth Systems
SKIN
$99.5M
– –
-825,109
Closed -$9.73M
TEVA icon
91
Teva Pharmaceuticals
TEVA
$40.6B
– –
-683,613
Closed -$5.52M
VTYX
92
DELISTED
Ventyx Biosciences
VTYX
– –
-125,000
Closed -$4.36M
CTLT
93
DELISTED
CATALENT, INC.
CTLT
– –
-235,320
Closed -$17M
BLU
94
DELISTED
BELLUS Health Inc.
BLU
– –
-214,661
Closed -$2.27M
RXDX
95
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
– –
-123,599
Closed -$8.01M
1 2 3
4

Similar funds

DCM
Defilade Capital Management Emeryville, California $712M AUM
AMPWP
Alvarez & Marsal Private Wealth Partners West Palm Beach, Florida $712M AUM
DCM
Dimension Capital Management Coral Gables, Florida $713M AUM 18.57% 1-Year Est. Return
PCS
Personal CFO Solutions Chester, New Jersey $712M AUM 25.3% 1-Year Est. Return
ACGDR
Atmos Capital Gestao de Recursos Leblon - Rio De Janeiro, Brazil $714M AUM 35.97% 1-Year Est. Return
GEA
Glen Eagle Advisors Kingston, New Jersey $714M AUM 18.87% 1-Year Est. Return
ECM
EagleClaw Capital Management Boston, Massachusetts $714M AUM 24.24% 1-Year Est. Return
SSP
Sixth Street Partners Dallas, Texas $711M AUM 9.3% 1-Year Est. Return

Tri Locum Partners's Q4 2022 Portfolio in Review

As of Q4 2022, Tri Locum Partners held 95 positions worth $247M, down 32% from $364M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Tri Locum Partners withdrew a net $139M in Q4 2022, closing 22 positions and reducing 11 holdings. Its most notable exit was Biogen, an estimated $24.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 93% a quarter earlier, followed by Real Estate and Industrials.

Against the trend, Tri Locum Partners opened a new position in West Pharmaceutical worth $22.8M.

  • Tri Locum Partners's largest Q4 2022 buy was West Pharmaceutical: 97,084 shares worth $22.8M.
  • Tri Locum Partners added most to Sarepta Therapeutics in Q4 2022, an estimated $2.81M increase.
  • Tri Locum Partners's biggest Q4 2022 reduction was argenx, cutting an estimated $23.5M.
  • Tri Locum Partners fully exited Biogen in Q4 2022, selling an estimated $24.2M.
  • Tri Locum Partners's ten largest holdings make up 58% of its $247M portfolio in Q4 2022.
  • Tri Locum Partners opened 54 new positions and closed 22 in Q4 2022.
  • Tri Locum Partners's portfolio value fell 32% quarter-over-quarter to $247M.

Based on Tri Locum Partners's 13F filing for Q4 2022, filed 14 Feb 2023.